Methods for detecting activity of clottings factors
Whole blood assays and kits are described for evaluating dosage of factor VIIa or activated protein C, as well as for monitoring responsiveness to factor VIIa or activated protein C.
1. A method for managing anticoagulation therapy in a patient in need thereof, said method comprising administering an acute phase anticoagulant to said patient during the acute phase of coagulation; and administering a chronic phase anticoagulant to said patient during the chronic phase of coagulation wherein said chronic phase anticoagulant is an active-site inhibited factor VIIa linked to a PEG polymer, and wherein said active-site inhibition is effected by linkage of an active-site inhibition reagent to the active site of factor VIIa.
2. The method of claim 1 , wherein said acute phase is during surgery.
3. The method of claim 1 , wherein said acute phase anticoagulant is heparin.
4. The method of claim 1 , wherein said active-site inhibited factor VIIa polypeptide contains a substitution of a glutamine for proline at position 10 and a glutamic acid for lysine at position 32.
5. The method of claim 1 , wherein said acute phase is during catheterization or angioplasty.
6. The method of claim 1 , wherein said PEG polymer is linked via the active-site of said factor VIIa polypeptide.
7. The method of claim 1 , wherein the active-site inhibition reagent is a chloromethylketone-derivatized amino acid or peptide.